Gilead Sciences, Inc. (NASDAQ:GILD) Stake Lessened by Cerity Partners LLC

Cerity Partners LLC trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 32.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 171,841 shares of the biopharmaceutical company's stock after selling 82,031 shares during the period. Cerity Partners LLC's holdings in Gilead Sciences were worth $15,428,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Nicolet Advisory Services LLC increased its position in Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock worth $322,000 after buying an additional 100 shares during the period. Southland Equity Partners LLC increased its stake in shares of Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock worth $289,000 after acquiring an additional 110 shares during the period. Berkshire Bank increased its position in Gilead Sciences by 3.4% during the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC lifted its holdings in Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after acquiring an additional 112 shares during the period. Finally, Howe & Rusling Inc. lifted its stake in shares of Gilead Sciences by 2.5% in the fourth quarter. Howe & Rusling Inc. now owns 4,704 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Remove Ads

Gilead Sciences Stock Up 2.5 %

Gilead Sciences stock traded up $2.56 during midday trading on Monday, hitting $106.19. The stock had a trading volume of 1,245,206 shares, compared to its average volume of 7,477,106. The stock has a market cap of $132.22 billion, a P/E ratio of 287.00, a P/E/G ratio of 0.71 and a beta of 0.32. The business has a fifty day moving average price of $108.34 and a 200 day moving average price of $96.89. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a $0.79 dividend. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.98%. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last three months. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms recently weighed in on GILD. Morgan Stanley raised their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. Oppenheimer raised their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a report on Tuesday, March 4th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.